<- Go Home
RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Market Cap
$35.7M
Volume
188.3K
Cash and Equivalents
$10.0M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$629.0K
Profit Margin
67.78%
52 Week High
$1.69
52 Week Low
$0.75
Dividend
N/A
Price / Book Value
4.42
Price / Earnings
-2.82
Price / Tangible Book Value
4.42
Enterprise Value
$25.8M
Enterprise Value / EBITDA
-2.25
Operating Income
-$11.6M
Return on Equity
146.61%
Return on Assets
-68.39
Cash and Short Term Investments
$10.0M
Debt
$134.0K
Equity
$8.1M
Revenue
$928.0K
Unlevered FCF
-$6.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium